|
The European
Commission, the executive arm of the European
Union (EU), the European Patent Office (EPO)
and the European Medicines Agency (EMEA)
will be present at the BIO 2006 Annual International
Convention in Chicago (9-12 April 2006). A
joint EU Pavilion will highlight Europe’s
role in supporting research and innovation in the life
sciences and promote Europe as a highly competitive
knowledge-based economy with opportunities for research,
partnering and business.
At the EU Pavilion (Stand #241), experts
from Europe will give hands-on advice to anyone interested
in doing life sciences research and business
in Europe.
The BIO International Convention 2006
is organised by BIO. The BIO organisation
represents more than 1100 biotechnology companies, academic
institutions, state biotechnology centers and related
organizations across the United States and 31 other
nations. BIO members are involved in the research and
development of healthcare, agricultural, industrial
and environmental biotechnology products. More info:
www.bio.org/events/2006
|
BROCHURE: "Life
Sciences and Biotechnology for Europe" (PDF,
378 kB)
AGENDA: "Europa at
BIO 2006"
BIO related NEWS
AGENDA:
Europe at BIO 2006 (
391 kB)
| On
BIO’s International Day (9 April
2006) the EU will participate in the Ministerial Conference,
the Global Biotechnology Forum and discuss the following
issues: |
| |
|
Sunday,
9 April 2006 |
International Day
On
BIO’s International Day EU representatives
will speak at the Ministerial Conference and
the Global Biotechnology Forum. The dedicated
EU track at the International Day has 4 sessions
on:
R&D Collaboration with the EU
(organised by
DG Research of the
European Commission)
Regulatory Issues in the EU
(organised by
DG Research and
DG Enterprise and Industry of the
European Commission, together with the
European Medicines Agency)
Intellectual Property Rights (IPR) in
Europe
(organised by the
European Patent Office)
The Co-existence of GM and non-GM in the EU
(organised by the
Joint Research Centre (JRC) of the EU)
(Sessions
fact sheet including speakers and session abstracts
-
156 KB) |
Monday,
10 April 2006 |
Intellectual Property/Legal
Track > [2:00 pm – 3:30 pm]:
What's new?
Perspectives to and from the JPO, EPO and USPTO
|
| Regenerative Medicine
Track > [4:00 pm – 5:30 pm]:
Stem Cell Research in Europe: How Do Industry
and Academia Collaborate?
(Session
fact sheet including abstract and speakers's bio
-
103 KB)
|
Tuesday,
11 April 2006 |
Doing Business Globally
Track > [11:00 am – 12:30 pm]:
Excellence Through Partnerships: EU Research
Funding for Biotech R&D
(Session
fact sheet including abstract and speakers's bio
-
96 KB)
|
Policy Track > [2:00
pm – 3:30 pm]:
Food and feed; fiber & fuels
- Global challenges of the knowledge-based bio-economy
|
Regulatory Track > [2:00
pm – 3:30 pm]:
How Will Europe and
the United States Regulate Emerging Advanced Therapies?
|
Wednesday,
12 April 2006 |
Regulatory Track > [11:00
am – 12:30 pm]:
Innovative Approaches to Improve
Drug R&D in the European Union and the United
States - One Year On |
| |
|
Tuesday,
11 April 2006
|
Press conference
> [9:00 am – 9:45 pm]:
The evolving landscape
for biotechnology in Europe: research, regulations, IPR
Room 106A, South Building, McCormick Place Convention
Center |
European Commission
The European Commission is largely responsible for managing
the EU's common policies, i.e. research, agriculture, trade,
development aid, etc. It also manages the budget for these
policies. The Commission has developed a Strategy for the
European Union on Life Sciences and Biotechnology with policy
measures and a 30-point action plan. For instance, within
the Sixth Research Framework Programme (FP6, 2002-2006) the
EU has earmarked some €3 billion (~$4 billion) for research
in life sciences. These funds are allocated mainly through
competitive calls inviting proposals for collaborative R&D
projects in a variety of areas, including genomics, biotechnology
and agro-food applications. Researchers from almost every
country (25 EU Member States plus associated countries like
e.g. Switzerland and Turkey, as well as countries with science
and technology (S&T) cooperation agreements, like e.g.
the US, Canada) are welcome to participate in collaborative
research projects with Europeans.
Several departments (directorates-general, DG) of the European
Commission are involved in EU policies to support life sciences
and biotechnology in Europe: the Secretariat-General, the
Research DG, the Joint Research Centre (JRC), the Enterprise
and Industry DG and the Agriculture and Rural Development
DG.
More info on the European Commission: ec.europa.eu/index_en.htm.
European Patent Office
The mission of the European Patent Office (EPO) is to support
innovation, competitiveness and economic growth in Europe.
Its task is to grant European patents for inventions on the
basis of a centralized procedure for the contracting states
to the European Patent Convention (EPC), which is in force
since 1977. The EPO is the executive arm of the European Patent
Organization, an intergovernmental body set up under the EPC,
whose members are the EPC contracting states. The activities
of the Office are supervised by the Organization’s Administrative
Council, which is composed of the delegates from the contracting
states. The EPO has its headquarters in Munich, a branch at
The Hague and offices in Berlin and Vienna. With its workforce
of nearly 6 500 staff, the EPO is one of the largest European
institutions. The EPC states currently are all EU member states
plus Bulgaria, Switzerland, Iceland, Liechtenstein, Monaco,
Romania and Turkey. European patent applications and patents
can also be extended at the applicant’s request to Albania,
Bosnia and Herzegovina, Croatia, Latvia, the Former Yugoslav
Republic of Macedonia, Serbia and Montenegro. European patents
cover a geographical area of more than 540 million inhabitants.
More info on the European Patent Office:
www.epo.org.
European Medicines Agency
The European Medicines Agency (EMEA) is an executive agency
of the European Union. It contributes to the protection of
public and animal health by ensuring that medicines for human
and veterinary medicines are safe, effective and of high quality.
Bringing together the scientific resources of the EU and EEA-EFTA
Member States in a network of more than 40 national competent
authorities, the EMEA coordinates the evaluation and supervision
of medicines throughout the EU. The Agency cooperates closely
with international partners, reinforcing the EU contribution
to global harmonization. The scientific opinions of the Agency
are prepared by four committees: the Committee for Medicinal
Products for Human Use (CHMP), the Committee for Medicinal
Products for Veterinary use (CVMP), the Committee on Orphan
Medicinal Products (COMP), responsible for the designation
of 'orphan' medicines for rare diseases, and the Committee
on Herbal Medicinal Products (HMPC) responsible for the formulation
of scientific opinions on traditional herbal medicines. A
network of more than 3,500 European experts underpins the
scientific work of the EMEA and its committees.
More info on the European Medicines Agency
(EMEA, London): www.emea.eu.int.
|
